关于江煮减轻2型糖尿病患者认知功能障碍的机制的研究
Qiyue Yang1, Qiwei Luo2, Wenrui Xia1
1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, PR China.
Journal of ethnopharmacology
|December 26, 2024
概括
-- (YGJ) 可以通过调节肠道微生物群和胆酸代谢,减少炎症和改善代谢健康来改善2型糖尿病的认知功能.
科学领域:
- 药理学和中国传统医学
- 神经科学和内分泌学
- 微生物组研究 微生物组研究
背景情况:
- 江 (Yi-guan-jian decoction,简称YGJ) 是一种传统的中医药,用于治疗肝脏和脏的阴性缺陷.
- 在减轻与2型糖尿病 (T2DM) 相关的认知功能障碍方面,YGJ显示出有前途.
研究的目的:
- 阐明YGJ减轻T2DM认知功能障碍的精确机制.
- 研究YGJ对T2DM大鼠肠道微生物群,胆酸代谢和相关分子通路的影响.
主要方法:
- 给T2DM大鼠服用不同剂量的YGJ,持续8周,作为阳性对照对象使用甲福明和美曼丁.
- 使用莫里斯水迷宫测试评估认知功能.
- 分析了肠道微生物群的组成,胆酸概况,炎症标记物,神经递质和胆酸受体表达 (FXR,PXR,VDR,TGR5).
主要成果:
- 在T2DM大鼠中,YGJ显著改善了认知功能,降低了胰岛素抵抗,高脂血症和炎症标志物.
- YGJ调节了关键肠道细菌的丰富度,这些细菌参与了胆酸代谢 (例如,Romboutsia, Bacteroides).
- YGJ通过影响肠道受体FXR,PXR,VDR和TGR5.5来调节胆酸代谢.
结论:
- YGJ通过改善葡萄糖平衡,胰岛素敏感性,脂质代谢和神经炎症来缓解T2DM中的认知功能障碍.
- YGJ通过重塑肠道微生物群和胆汁酸组成,并调节肠道胆汁酸受体来发挥其治疗作用.
- YGJ代表了T2DM认知功能障碍的潜在补充和替代疗法.
更多相关视频
相关概念视频
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
01:22Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
01:15Diabetes: Management and Pharmacotherapy
234
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
234
01:36Carbohydrate Metabolism
10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
01:23Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162